T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

In the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) clinical trial (NCT01631214), 1 year of romosozumab followed by alendronate reduced the risk of vertebral and nonvertebral fractures compared to alendronate alone in women with prevalent fracture. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosman, Felicia, Lewiecki, E Michael, Ebeling, Peter R, Hesse, Eric, Napoli, Nicola, Matsumoto, Toshio, Crittenden, Daria B, Rojeski, Maria, Yang, Wenjing, Libanati, Cesar, Ferrari, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328657/
https://www.ncbi.nlm.nih.gov/pubmed/32445228
http://dx.doi.org/10.1002/jbmr.3996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328657/
https://www.ncbi.nlm.nih.gov/pubmed/32445228
http://dx.doi.org/10.1002/jbmr.3996

Ejemplares similares